Top Story Today
500 Patients a Year Just Got a Second Shot at Survival
The FDA approved Decnupaz (pivekimab sunirine), a first-in-class antibody-drug conjugate for BPDCN, a blood cancer so rare that most oncologists never encounter it. In newly diagnosed patients, roughly 70 to 75% achieved complete remission, and 53% were able to bridge to a stem cell transplant, the closest thing to a cure. The drug targets the same protein (CD123) as the only other approved therapy but works through a totally different mechanism and carries no risk of capillary leak syndrome, the scary side effect that shadows the existing treatment. For AbbVie, it also validates the ADC platform it acquired through the ImmunoGen deal.
Why it matters: BPDCN patients now have two targeted therapies with different mechanisms and safety profiles, giving doctors real sequencing options for the first time. The approval also reinforces the FDA's willingness to greenlight drugs for ultra-rare cancers based on small, single-arm trials when the unmet need is severe enough.
Read more →Clinical Breakthroughs
GSK's Hep B Drug Might Actually End the 'Pills Forever' Era
For a disease affecting 254 million people with zero approved cures, GSK just posted a milestone: bepirovirsen hit its primary endpoint in two Phase 3 trials, achieving functional cure in a subset of chronic hepatitis B patients after six months of treatment. The drug strips the virus of its immune-cloaking surface protein, letting the body's own defenses finish the job. Analysts see blockbuster potential north of 2 billion pounds in peak sales.
Read more →A Korean Biotech's MASH Numbers Just Landed in Semaglutide Territory
D&D Pharmatech reported that 50% of patients on its dual GLP-1/glucagon drug zabopegdutide reversed liver scarring in a Phase 2 trial, with 62.5% seeing full MASH resolution versus 5.3% on placebo. The numbers rival Novo Nordisk's semaglutide, but only 16 patients were evaluable on the treatment dose. Promising signal, tiny sample: the classic biotech cliffhanger.
Read more →Regulatory and Policy
COVID Vaccines Are Officially Boring Now (and That's the Point)
The FDA's vaccine advisory committee met to pick the strain for 2026-2027 COVID shots, with a recombinant variant called XFG emerging as the frontrunner. Moderna says it can have doses ready by mid-August. The bigger concern: uptake of the updated shot among U.S. adults remained low last season, turning the annual COVID vaccine into a flu-shot-style ritual with shrinking audiences.
Read more →The FDA Wants to Inspect Your Drug Factory in a Single Day
With roughly 2,000 facilities uninspected since before the pandemic, the FDA launched a pilot using AI risk analytics to conduct one-day inspections at low-risk sites. About 46 speed-round visits have been completed so far, with most facilities passing cleanly. The agency says it won't replace traditional deep dives for high-risk operations, but regulatory lawyers want more transparency into how the AI defines "low risk."
Read more →Startups and Tools
94% of Brain Drugs Fail. This Startup Blames the Trials, Not the Science.
Kordata Dynamics emerged from stealth with an AI platform purpose-built for CNS clinical trials, where success rates hover around 6%. Its NeuroTune engine processes real-time neural signals to replace subjective rating scales with biological data. The catch: it's pre-seed, unproven in completed trials, and launching its first site in Bakersfield rather than Boston.
Read more →